Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 2, 2008, Pages 235-239

  Castanheira, Mariana ^a   Jones, Ronald N ^a,b   Sader, Hélio S ^a,c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Daptomycin; MRSA; Vancomycin resistance

Indexed keywords

AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CANADA; CONTROLLED STUDY; GRAM POSITIVE BACTERIUM; HOSPITAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA;

EID: 43549124333     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.016     Document Type: Article

References (12)

1. Boucher H.W., and Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45 (2007) 601-608
2. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38 (2004) 994-1000
3. Clinical and Laboratory Standards Institute. M7-A7, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 7th ed. (2006), CLSI, Wayne, PA
4. Clinical and Laboratory Standards Institute. M100-S17, Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement (2007), CLSI, Wayne, PA
5. Friedman L., Alder J.D., and Silverman J.A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (2006) 2137-2145
6. Jorgensen J.H., and Crawford S.A. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J. Clin. Microbiol. 44 (2006) 2126-2129
7. Kanafani Z.A., and Corey G.R. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev. Anti. Infect. Ther. 5 (2007) 177-184
8. Pillai S.K., Gold H.S., Sakoulas G., Wennersten C., Moellering Jr. R.C., and Eliopoulos G.M. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51 (2007) 2223-2225
9. Sader H.S., and Jones R.N. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin. Infect. Dis. 43 (2006) 798-799
10. Sader H.S., Fritsche T.R., and Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 2330-2336
11. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering Jr. R.C., and Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 1581-1585
12. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60 (2007) 788-794